New injection JL19001 enters early human testing for tough cancers
NCT ID NCT07603479
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a shot under the skin, either alone or with standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.